BioIntervene Announces $30 Million Series A Financing − Proceeds to advance portfolio of selective A3 adenosine receptor agonists through human proof-of-concept studies − − Company appoints Dr. Charles Cohen as Chief Scientific Officer − SAN DIEGO,...